Abstract
Objective We examined the clinical and serologic features of Guillain-Barré syndrome (GBS)-related diseases (GBSRDs), including GBS, Fisher syndrome (FS), and Bickerstaff brainstem encephalitis (BBE), after influenza virus infection (GBSRD-I) to reveal potential underlying autoimmune mechanisms.
Methods We retrospectively investigated the presence of antiglycolipid antibodies against 11 glycolipids and the clinical features of 63 patients with GBSRD-I. Autoantibody profiles and clinical features were compared with those of 82 patients with GBSRDs after Campylobacter jejuni infection (GBSRD-C).
Results The anti-GQ1b seropositivity rate was significantly higher, whereas the GM1 and GD1a seropositivity rates were significantly lower in GBSRD-I compared with GBSRD-C. Anti-GQ1b and anti-GT1a were the most frequently detected antiglycolipid antibodies in GBSRD-I (both 15/63, 24%). Consequently, FS was more frequent in GBSRD-I than GBSRD-C (22% vs 9%, p < 0.05). In addition, as for GBS, cranial nerve deficits, sensory disturbances, and ataxia were more frequent in the cases after influenza infection (GBS-I) than in those after C. jejuni infection (GBS-C) (46% vs 15%, 75% vs 46%, and 29% vs 4%, respectively; all p < 0.01). Nerve conduction studies revealed acute inflammatory demyelinating polyneuropathy (AIDP) in 60% of patients with GBS-I but only 25% of patients with GBS-C (p < 0.01).
Conclusions Anti-GQ1b antibodies are the most frequently detected antibodies in GBSRD-I. Compared with GBS-C, GBS-I is characterized by AIDP predominance and frequent presence of cranial nerve involvement and ataxia.
Glossary
- AIDP=
- acute inflammatory demyelinating polyneuropathy;
- AMAN=
- acute motor axonal neuropathy;
- BBE=
- Bickerstaff brainstem encephalitis;
- FS=
- Fisher syndrome;
- GBS=
- Guillain-Barré syndrome;
- GBS-C=
- Guillain-Barré syndrome after C. jejuni infection;
- GBS-I=
- Guillain-Barré syndrome after influenza virus infection;
- GBSRD=
- Guillain-Barré syndrome–related disease;
- GBSRD-C=
- Guillain-Barré syndrome–related disease after C jejuni infection;
- GBSRD-I=
- Guillain-Barré syndrome–related disease after influenza virus infection;
- HA=
- hemagglutinin;
- NA=
- neuraminidase;
- NCS=
- nerve conduction study;
- RIDT=
- rapid influenza diagnostic test
Guillain-Barré syndrome (GBS) is an acute acquired autoimmune disorder of the peripheral nerves that frequently develops after infection. For instance, antecedent infection such as Campylobacter jejuni, cytomegalovirus, or Mycoplasma pneumoniae is observed in approximately 70% of patients with GBS. Alternatively, GBS following influenza virus infection (GBS-I) is relatively rare.1 However, influenza virus infection is a common respiratory syndrome across all age groups. Influenza is also known to cause neurologic complications such as encephalitis, encephalopathy, and Reye syndrome that require differential diagnosis.2 In addition, several reports have shown that influenza virus infection or influenza-like illness can also cause Fisher syndrome (FS) and Bickerstaff brainstem encephalitis (BBE),3,–,5 which are caused by the pathogenetic mechanisms similar to those of GBS. Here, we call GBS, FS, and BBE as GBS-related diseases (GBSRDs).
Antiglycolipid antibodies are elevated in GBSRD and are strongly implicated in the pathogenesis. Antibodies against GM1 on the neuronal membrane ganglioside are often detected in GBS after C. jejuni infection, and antibodies to galactocerebroside (Gal-C) are often detected in neurologic diseases following M. pneumoniae infection.6,7 The structures of these carbohydrates are similar to carbohydrates expressed by the infectious agents, suggesting that a form of molecular mimicry is responsible for GBS-associated autoimmunity.8,9 In contrast to GBS associated with C. jejuni and M. pneumoniae infection, the clinical and serologic features of GBSRD and GBS after influenza virus infection (GBSRD-I and GBS-I, respectively) have not been described in detail. The purpose of this study is to investigate the unique clinical and serologic features of GBSRD-I and GBS-I.
Methods
Patients with GBSRD-I
We collected clinical information and acute-phase serum samples from consecutive patients who are diagnosed with GBSRD-I. These serum samples were sent to our laboratory from multiple hospitals in Japan between October 2009 and February 2017 for the examination of antiglycolipid antibodies. GBS and BBE were diagnosed according to previously presented criteria,10,11 and FS was diagnosed according to the clinical triad of acute progressive ophthalmoplegia, ataxia, and areflexia without limb weakness or impairment of consciousness. Patients with the FS triad and limb weakness were included in the GBS subgroup. In all patients with GBSRD, influenza virus infection was diagnosed by an immunochromatography-based rapid influenza diagnostic test (RIDT) within 4 weeks of the onset of symptoms. Immunochromatography-based RIDT detects nucleoprotein, which is one of the most abundant proteins in influenza virus and has fewer mutations than hemagglutinin (HA) and neuraminidase (NA). Although there are some differences in the detection rate, RIDT can detect various subtypes of influenza virus such as H1N1, H3N2, type B seasonal viruses, and pandemic H1N1 2009 viruses.12 The sensitivity of the RIDTs is approximately 60%, and the specificity is higher than 95%.13 Patients with GBSRD-I with antecedent gastrointestinal infectious symptoms were excluded from the study.
Clinical and electrophysiological assessment
The clinical and electrophysiological data of each patient with GBS were obtained retrospectively from the original attending neurologist or pediatrician using a questionnaire. According to the Ho criteria, nerve conduction study (NCS) findings were used to classify cases as acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), or unclassified.14 NCSs were performed at each participating hospital in a median of 8.5 days (range [1–20] days) after GBS symptom onset.
Antiglycolipid antibodies
Serum IgG antibodies to 11 glycolipid antigens (GM1, GM2, GM3, GD1a, GD1b, GD3, GT1b, GQ1b, GT1a, Gal-C, and GalNAc-GD1a) were examined in all patients by ELISA, as previously described.15
Patients with GBSRD-C
Clinical and serologic features of GBSRD-I and GBS-I were compared with those of GBSRD and GBS after C. jejuni infection (GBSRD-C and GBS-C, respectively). The antiglycolipid antibodies of these patients with GBSRD-C were tested in our laboratory between September 2012 and April 2017. C. jejuni infection was diagnosed by fecal culture or C. jejuni antibody test.
Statistical analysis
Differences in proportions were evaluated using the χ2 test or Fisher exact test, and differences in the median were evaluated using the Mann-Whitney U test. p < 0.05 (2 tailed) was considered significant for all tests. Statistical calculations were performed using SPSS version 2.0 (IBM, Japan).
Study approval and patient consent
This study was approved by the Internal Review Board of Kindai University Faculty of Medicine. All participants provided written informed consent.
Data availability
Anonymized data not published within the article will be shared by request from any qualified investigator.
Results
Comparison of GBS subtype and antiglycolipid antibody profile between GBSRD-I and GBSRD-C
The classic form of GBS (GBS-I or GBS-C according to the antecedent pathogen) was the most common disease subtype in both GBSRD-I and GBSRD-C groups (48/63 [76%] vs 74/82 [90%]), while BBE was rare in both groups (1 patient per group). In contrast, FS was significantly more prevalent in the GBSRD-I group compared with the GBSRD-C group (14/63 [22%] vs 7/82 [9%], p = 0.02).
Antiglycolipid antibodies were detected more frequently in patients with GBSRD-C than in patients with GBSRD-I (51/82 [62%] vs 25/63 [40%]; p < 0.01) (table 1). There were also significant differences in seropositivity rates for specific antiglycolipid antibodies between groups. Anti-GM1 antibody was substantially more common in GBSRD-C than in GBSRD-I (24/82 [29%] vs 3/63 [5%]; p < 0.01). Similarly, seropositivity for anti-GD1a was more frequent in GBSRD-C (18/62 [22%] vs 1/63 [2%]; p < 0.01). In contrast, anti-GQ1b was significantly more frequent in GBSRD-I than in GBSRD-C (15/63 [24%] vs 7/82 [9%]; p < 0.05). Anti-GT1a was also relatively common in GBSRD-I (24%), although the seropositivity rate did not differ significantly from patients with GBSRD-C (18%). Among the 15 patients with GBSRD-I seropositive for anti-GQ1b, 10 were diagnosed with FS. In patients with GBS-I, anti-GD1b was the most frequently detected autoantibody (7/48, 15%) (table 2).
Demographic and basic clinical features of the GBSRD-I and GBSRD-C groups
Comparison of antiglycolipid antibody profile between patients with GBSRD-I and GBSRD-C
Clinical features of GBS-I
The clinical features of GBS-I (n = 48) and GBS-C are summarized in table 3. Compared with patients with GBS-C, patients with GBS-I demonstrated a substantially lower antiglycolipid antibody seropositivity rate (29% vs 59%, p < 0.01). Conversely, cranial nerve deficits, sensory disturbances, and ataxia were significantly more frequent in GBS-I than in GBS-C (46% vs 15%, 75% vs 46%, and 29% vs 4%, respectively; p < 0.01). There were no significant differences in age, sex ratio, autonomic disturbance frequency, and the requirement for artificial ventilation between GBS-I and GBS-C subgroups.
Comparison of clinical characteristic between patients with GBS-I and GBS-C
We also obtained the NCS findings from 30 patients with GBS-I. According to the Ho criteria, 18 cases were classified as AIDP and 12 were unclassified, whereas no case was classified as AMAN. The proportion with AIDP was significantly higher in the GBS-I subgroup than in the GBS-C subgroup (p < 0.01). Among patients with GBS-I, there were no significant differences in demographic or clinical features between those infected with influenza virus A or B.
Discussion
GBSRD is presented after not only gastrointestinal infection but also upper respiratory infection. However, most of the antecedent infectious agents of upper respiratory infection are not identified. In the present study, we focused on influenza virus infection and report the distinct clinical and serologic features of GBSRD-I and GBS-I.
Anti-GQ1b and anti-GT1a were the most frequently detected antiglycolipid antibodies in GBSRD-I. GQ1b is densely localized in the paranodal regions of III, IV, and VI human cranial nerves. Therefore, anti-GQ1b antibody can cause ophthalmoplegia, which is one of the major symptoms of FS.16 In accord with this, FS was more frequent in GBSRD-I than GBSRD-C.
Compared with GBS-C, GBS-I is characterized by more frequent cranial nerve deficits, sensory disturbances, and ataxia. In addition, NCS findings revealed demyelinating neuropathy in a higher proportion of GBS-I cases than GBS-C cases. Furthermore, the frequency of AIDP was higher in GBS-I than in all GBS cases previously reported by a prospective cohort study in Japan (60% vs 40%).17 This is compatible with the results that GM1 and GD1a seropositivity rates were significantly lower in GBSRD-I compared with GBSRD-C. Besides, compared with cases with GBSRDs after M. pneumoniae infection (GBSRD-M) reported recently,7 the clinical and serologic features of GBSRD-I were somewhat different from those of GBSRD-M, in which the anti-GQ1b antibody positive rate and the frequency of FS cases were lower, and the anti-Gal-C antibody positive rate was higher than in GBSRD-I.
Previous reports (summarized in table 4) also found more frequent cranial nerve deficits (8/19, 42%) and sensory disturbance (15/19, 79%) in GBS-I. Moreover, these NCSs revealed demyelinating neuropathy in some patients with GBS-I (5/13, 38%), whereas axonal neuropathy was relatively less common (2/13, 15%).1,18,–,23 Those are in accord with the current findings.
Clinical summary of previously reported patients with GBS-I
Influenza viruses A and B are wrapped by a lipid bilayer envelope containing various glycoproteins, including HA and NA. Therefore, antiglycolipid antibodies may be produced by influenza virus infection because of possible molecular mimicry between glycoproteins of influenza viruses and glycolipids localized in human peripheral nerves.
The main limitation of this study is that we could not completely exclude the possible coexistence of other infections. Selection bias by attending physicians also could exist. In addition, we could not evaluate whether the severity and infection period of influenza virus infection are associated with the severity of GBS-I because the study was retrospectively conducted. A future prospective study is needed to clarify those issues. However, this study enrolled a relatively large number of patients, all with confirmed influenza infection. Therefore, clinical characteristics should reflect GBS-I and GBSRD-I.
In conclusion, antiglycolipid antibodies are detected in some GBSRD-I cases, and anti-GQ1b and anti-GT1a antibodies are the most frequent. Compared with GBS-C, GBS-I is characterized by more frequent AIDP, cranial nerve deficits, sensory disturbances, and ataxia. Further investigation is required to clarify the pathomechanisms of GBSRD-I.
Author contributions
M. Yamana has contributed to acquisition, analysis, and interpretation of data and drafted the manuscript. M. Kuwahara has analyzed and interpreted data and also participated in drafting the manuscript and revising it. Y. Fukumoto, K. Yoshikawa, and K. Takada have contributed to acquisition of data. S. Kusunoki has made substantial contributions to conception and design of the study and also revised the manuscript critically for important intellectual content. S. Kusunoki made final approval of the manuscript.
Study funding
This work was supported by the Ministry of Education, Culture, Sports, Science and Technology of Japan (Grants-in-Aid for Scientific Research, 18H02745), the Ministry of Health, Labour and Welfare of Japan (Health and Labour Sciences Research Grant on Rare and Intractable Diseases [Validation of Evidence-based Diagnosis and Guidelines, and Impact on QOL in Patients with Neuroimmunological Diseases]), and Intramural Research Grant (28-5) for Neurological and Psychiatric Disorders of NCNP.
Disclosure
None of the authors report any disclosures relevant to the manuscript. Disclosures available: Neurology.org/NN.
Footnotes
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by the authors.
- Received January 4, 2019.
- Accepted in final form April 5, 2019.
- Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
References
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
